Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
This study is currently recruiting participants.
Verified by Dyax Corporation, January 2009
First Received: April 4, 2007   Last Updated: January 7, 2009   History of Changes
Sponsored by: Dyax Corporation
Information provided by: Dyax Corporation
ClinicalTrials.gov Identifier: NCT00456508
  Purpose

The purpose of this study is to evaluate the efficacy and safety of repeated doses of ecallantide in the treatment of acute attacks of hereditary angioedema and to allow HAE patients continued access to ecallantide. In addition, patients enrolled in DX-88/20 (EDEMA4) trial will be followed up and treated for subsequent attacks in this trial.


Condition Intervention
Hereditary Angioedema
Drug: ecallantide

Genetics Home Reference related topics: hereditary angioedema
MedlinePlus related topics: Edema
Drug Information available for: Ecallantide
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: Open-Label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks

Further study details as provided by Dyax Corporation:

Primary Outcome Measures:
  • Change in symptom severity as reported by the patient [ Time Frame: 4 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Patient reported symptom change [ Time Frame: 4 hours ] [ Designated as safety issue: No ]
  • Time to improvement [ Time Frame: 4 hours ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: April 2007
Estimated Study Completion Date: December 2009
Estimated Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
DX-88 (ecallantide)
Drug: ecallantide
solution for SC injection, one 30 mg dose per HAE attack

Detailed Description:

This is an open label trial.

The study is designed to assess the efficacy and safety of 30 mg subcutaneous ecallantide in the treatment of acute attacks of hereditary angioedema.

This study is designed to provide efficacy and safety data on repeated use of ecallantide. These data are intended to support the marketing authorization of ecallantide in the treatment of acute attacks of hereditary angioedema. Efficacy and safety of ecallantide will be evaluated in this study.

  Eligibility

Ages Eligible for Study:   10 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 10 years of age or older
  • Documented diagnosis of HAE (Type I or II)
  • Willing and able to give informed consent
  • Acute HAE attack at time of presentation

Exclusion Criteria:

  • Receipt of an investigational drug or device, within 30 days prior to study treatment, other than DX-88 (ecallantide)
  • Pregnancy or breastfeeding
  • Receipt of non-investigational C1-INH or DX-88 within 72 hours of treatment
  • Patients eligible for current, ongoing clinical trial in which DX 88 (ecallantide) is offered
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00456508

Contacts
Contact: EDEMA Administrator 1-888-675-9575 edemaadmin@dyax.com
Contact: EDEMA Administrator 1-617-250-5501

  Hide Study Locations
Locations
United States, Arizona
Aaron Davis Recruiting
Scottsdale, Arizona, United States, 85251
Contact: Aaron Davis            
United States, Arkansas
Arkansas Children's Hospital Recruiting
Little Rock, Arkansas, United States, 72202
Contact: Stacie Jones, MD            
Little Rock Allergy & Asthma Clinic Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Karl Sitz, MD            
United States, California
Jacob Offenberger Recruiting
Granada Hills, California, United States, 91344
Contact: Jacob Offenberger            
Pacific Coast Allergy Recruiting
Crescent City, California, United States, 95531
Contact: Christopher Chang            
UCLA David Geffen School of Medicine, Department of Medicine Recruiting
Los Angeles, California, United States, 90095-1680
Contact: Marc Riedl            
Alta Bates Summit Comprehensive Cancer Center Recruiting
Berkeley, California, United States, 94704
Contact: Usha Sunkara            
United States, Colorado
Asthma and Allergy Associates, P.C. Recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Daniel Soteres            
United States, Delaware
Christiana Hospital, Christiana Care Health Services Recruiting
Newark, Delaware, United States, 19718
Contact: Gregory Marcotte            
United States, District of Columbia
Georgetown University Medical Center, Georgetown University Hospital Recruiting
Washington, District of Columbia, United States, 20007
Contact: Aziza Shad            
United States, Florida
Roberson Allergy and Asthma Recruiting
West Palm Beach, Florida, United States, 33401
Contact: Clive Roberson            
University of Miami, General Clinical Research Center Recruiting
Miami, Florida, United States, 33136
Contact: Gary Kleiner            
University of South Florida, Asthma, Allergy and Immunology Clinical Research Unit Recruiting
Tampa, Florida, United States, 33613
Contact: Richard Lockey            
United States, Georgia
Allergy Center of Brookstone Recruiting
Columbus, Georgia, United States, 31904
Contact: Robert Chrzanowski, MD            
Family Allergy & Asthma Center, PC Recruiting
Atlanta, Georgia, United States, 30342
Contact: Robyn Levy, MD            
United States, Illinois
University Consultants in Allergy and Immunology Recruiting
Chicago, Illinois, United States, 60612
Contact: Mary Tobin            
United States, Indiana
Muncie Allergy Center Recruiting
Muncie, Indiana, United States, 47304
Contact: Sai Karlapudi, MD            
United States, Kansas
Kansas City Allergy & Asthma Recruiting
Overland Park, Kansas, United States, 66210
Contact: Mark Neustrom, DO            
United States, Maryland
Institute for Asthma and Allergy Recruiting
Wheaton, Maryland, United States, 20902
Contact: H. Henry Li, MD            
United States, Massachusetts
Brigham and Women's Hospital Recruiting
Chestnut Hill, Massachusetts, United States, 02467
Contact: Albert Sheffer            
United States, Michigan
Respiratory Medicine Research Institute of Michigan, PLC Recruiting
Ypsilanti, Michigan, United States, 48197
Contact: Jeffrey G. Leflein            
Asthma and Allergy Institutes of Michigan Recruiting
Clinton TWP, Michigan, United States, 48038
Contact: Jeffrey Bruner            
United States, Nevada
Nevada Access to Research and Education Society Recruiting
Las Vegas, Nevada, United States, 89102
Contact: Jim Christensen            
University of Nevada School of Medicine Recruiting
Reno, Nevada, United States, 89503
Contact: Mary Beth Hogan            
United States, New Jersey
UMDNJ- New Jersey Medical School Recruiting
Newark, New Jersey, United States, 07103
Contact: Leonard Bielory            
United States, New Mexico
Allergy Partners of Albuquerque Recruiting
Albuquerque, New Mexico, United States, 87109
Contact: Michael Keslin            
United States, New York
Winthrop University Hospital Recruiting
Mineola, New York, United States, 11501
Contact: Mark Davis-Lorton, MD            
United States, North Carolina
Allergy Partners of Western North Carolina Recruiting
Asheville, North Carolina, United States, 28801
Contact: Donald Russell, MD            
Contact: William McCann, MD            
United States, Ohio
Optimed Research, LLC Recruiting
Columbus, Ohio, United States, 43235
Contact: Donald McNeil, MD            
University of Cincinnati, Division of Internal Medicine Recruiting
Cincinnati, Ohio, United States, 45267
Contact: Jonathan Bernstein            
United States, Pennsylvania
Valley Clinical Research Center Recruiting
Easton, Pennsylvania, United States, 18045
Contact: Eric Schenkel, MD            
Penn State Milton S Hershey Medical Center Recruiting
Hershey, Pennsylvania, United States, 17033
Contact: Timothy Craig            
Asthma Allergy and Pulmonary Associates Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: John Cohn            
Children's Hospital of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Andrew MacGinnitie            
United States, Tennessee
Highlands Allergy and Asthma Center, PC Recruiting
Bristol, Tennessee, United States, 37620
Contact: Neil Wallen, MD            
United States, Texas
AARA Research Center Recruiting
Dallas, Texas, United States, 75231
Contact: William Lumry, MD            
The Paull Allergy and Asthma Clinic, P.A Recruiting
Bryan, Texas, United States, 77802
Contact: Keith Paull            
University of Texas Medical Branch Recruiting
Galveston, Texas, United States, 77555-1083
Contact: J. Andrew Grant            
Baylor Clinic, Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: David Huston            
United States, Utah
University of Utah Health Sciences Center Recruiting
Salt Lake City, Utah, United States, 84132-2409
Contact: Gerald Gleich            
United States, Virginia
Clinical Research Associates of Tidewater Recruiting
Norfolk, Virginia, United States, 23507
Contact: Duane G. Wombolt            
United States, Washington
Puget Sound Allergy, Asthma, & Immunology Recruiting
Tacoma, Washington, United States, 98405
Contact: Arthur Vegh, MD            
Canada, Ontario
Allergy and Asthma Research Centre Recruiting
Ottawa, Ontario, Canada, K1Y 4G2
Contact: William Yang            
University of Toronta Recruiting
Toronto, Ontario, Canada, M4V 1R2
Contact: Gordon Sussman            
Jordan
Jordan University Hospital Recruiting
Amman, Jordan, 1194
Contact: Mustafa Shennak            
Sponsors and Collaborators
Dyax Corporation
Investigators
Study Director: Patrick Horn, MD, PhD Dyax Corp.
  More Information

No publications provided

Responsible Party: Dyax Corp. ( Bill Pullman, MD, PhD, Executive Vice President, Chief Development Officer )
Study ID Numbers: DX-88/19
Study First Received: April 4, 2007
Last Updated: January 7, 2009
ClinicalTrials.gov Identifier: NCT00456508     History of Changes
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Hereditary Angioedema
Hypersensitivity
Genetic Diseases, Inborn
Skin Diseases
Angioedema
Hypersensitivity, Immediate
Vascular Diseases
Urticaria
Angioedema, Hereditary

Additional relevant MeSH terms:
Hypersensitivity
Skin Diseases, Vascular
Genetic Diseases, Inborn
Immune System Diseases
Skin Diseases
Angioedema
Hypersensitivity, Immediate
Vascular Diseases
Urticaria
Cardiovascular Diseases
Angioedema, Hereditary

ClinicalTrials.gov processed this record on May 13, 2009